Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
TG Therapeutics, Inc. (NASDAQ:TGTX), a pharmaceutical company with a market capitalization of $5.26 billion and impressive gross profit margins of 87%, announced the results of its 2025 Annual Meeting held on Thursday, June 12, 2025, via an online platform. According to InvestingPro data, the company has shown remarkable performance with a 123% return over the past year. Shareholders representing approximately 74.58% of the outstanding shares were present or represented by proxy, ensuring a quorum as required by law.
During the meeting, which was detailed in the company’s definitive proxy statement filed on April 30, 2025, several key proposals were voted on and approved.
The election of six directors to hold office until the 2026 annual meeting was confirmed, with votes for each director ranging from 47,757,163 to 75,488,727, translating to approval percentages between 54.12% and 85.55%. The votes withheld and broker non-votes were also reported for each director.
The ratification of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, received overwhelming support, with 117,836,086 votes for and only 442,199 against, along with 152,106 abstentions.
An advisory vote to approve the compensation of the company’s named executive officers yielded 47,864,737 votes for and 39,988,402 against, with 383,906 abstentions and 30,193,346 broker non-votes.
Finally, the amendment to the company’s 2022 Incentive Plan to increase the number of authorized shares of Common Stock authorized for issuance under the plan from 17,000,000 to 22,000,000 shares was approved with 82,034,592 votes for, 5,788,439 against, 414,014 abstentions, and 30,193,346 broker non-votes. The company maintains a strong financial position with a current ratio of 4.02, indicating healthy liquidity management.
TG Therapeutics, headquartered in New York, is incorporated in Delaware and focuses on pharmaceutical preparations. The company’s common stock is listed on the Nasdaq Capital Market under the symbol TGTX.
The information in this article is based on a press release statement from TG Therapeutics.
In other recent news, TG Therapeutics reported its first-quarter 2025 earnings, revealing a significant miss on earnings per share (EPS) but a slight beat on revenue expectations. The company’s EPS was $0.03, falling short of the projected $0.16, while revenue reached $119.7 million, surpassing the $117.13 million estimate. Despite the EPS shortfall, TG Therapeutics raised its full-year 2025 U.S. net revenue guidance to $560 million, reflecting confidence in continued revenue growth. Additionally, the company presented new data on its multiple sclerosis drug, BRIUMVI, at the Consortium of Multiple Sclerosis Centers meeting, focusing on long-term treatment safety and tolerability. The data showed no association between decreases in serum immunoglobulin levels and serious infections in long-term treatment. Jefferies analyst Roger Song maintained a Buy rating on TG Therapeutics with a price target of $46.00, citing the company’s solid financial position and potential for future success. The company’s financial strategy aims to maintain non-GAAP operating expenses at approximately $300 million for 2025, with a focus on achieving profitability through strong revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.